Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | CLYM Climb Bio, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $11.66 -1.9% | $14.86 -2.5% |
| StockIQ Score | 45D+ Moderate Risk: Medium | 36F Weak Risk: Medium |
| Technical | 19F | 13F |
| Fundamental | 46D+ | 35F |
| Growth | 57C | 50C- |
| Fair Value | 38F | 38F |
| News | 100A+ | 50C- |
| Quality | — | 50C- |
| Risk | 48D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Climb Bio (CLYM) outperforms Ascentage Pharma (AAPG) in most categories. Its technical score (65 vs. 18) and fundamental score (46 vs. 35) are significantly higher, showing stronger market trends and financial health. While growth scores are close (57 vs. 50), CLYM’s overall rating (Moderate) is stronger than AAPG’s Weak. Valuation scores are tied at 38.
